Rheumazentrum Ruhrgebiet

Recent papers from Rheumazentrum Ruhrgebiet

1. Bimekizumab-Treated Patients with Axial Spondyloarthritis Maintained Stringent Clinical Responses Over 3 Years: Phase 3 and Open-Label Extension ResultsThe Journal of Rheumatology · 2026
2. Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 StudyRheumatology and Therapy · 2026
3. Depressive symptoms are associated with achieving remission in PsA patients – an analysis from the RABBIT-SpA registerBMC Rheumatology · 2026
4. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyThe Lancet · 2018
5. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialThe Lancet · 2013
6. Arrhythmic risk in axial spondyloarthritis: a narrative reviewEULAR Rheumatology Open · 2026
7. Selection of relevant domains and instruments for the ASAS core set to assess axial spondyloarthritis in clinical practice: a Delphi survey of stakeholdersEULAR Rheumatology Open · 2026
8. Longitudinal fatigue outcomes and prediction in inflammatory arthritis: a real-world digital cohort studyRheumatology International · 2026
9. Obesity is more strongly associated with physical performance and body composition than sarcopenia in patients with spondyloarthritisLara D. Veeken · 2026
10. Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label ExtensionArthritis & Rheumatology · 2026
11. Conclusions from an integral equation about the prevalence-odds in the illness-death model for chronic diseases2026
12. Large language models show high clinical safety but differences in completeness for reproductive counselling in women with inflammatory rheumatic and musculoskeletal diseases: a comparative expert evaluationRheumatology International · 2026
13. Impact of bimekizumab on CANDEN spinal MRI inflammation and structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 resultsLara D. Veeken · 2026
14. Remission rates of patients with axial spondyloarthritis in a tertiary care centerThe Journal of Rheumatology · 2026
15. Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune–Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists‐Referred Multicenter German Registry CohortACR Open Rheumatology · 2026
16. Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referralsAnnals of the Rheumatic Diseases · 2026
17. Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the Psabiond Observational StudyThe Journal of Rheumatology · 2026
18. Disease Burden and Comorbidities in Patients with Psoriatic Arthritis and Concomitant Obesity – A Pooled Analysis of 3 Clinical TrialsThe Journal of Rheumatology · 2026
19. Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studiesAnnals of the Rheumatic Diseases · 2026
20. Psychosocial dimensions of pain in axial spondyloarthritis: Construct validity and responsiveness of the multidimensional pain inventory (MPI)Therapeutic Advances in Musculoskeletal Disease · 2026